Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, and its news flow reflects this GI specialization. Company updates frequently center on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) that Phathom markets in the United States for adult patients with Erosive GERD, Non-Erosive GERD, and Helicobacter pylori infection in combination regimens.
Investors and healthcare observers following PHAT news can expect regular announcements on commercial performance, including prescription milestones and revenue updates tied to VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Phathom’s press releases have highlighted metrics such as total VOQUEZNA prescriptions dispensed in the United States and quarterly financial results, often accompanied by commentary on commercialization strategy and expense trends.
Another major category of Phathom news involves clinical and scientific developments. The company reports progress in trials like the Phase 3 pHalcon-NERD-301 study in Non-Erosive GERD and the Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA in eosinophilic esophagitis. Publications in peer-reviewed journals and presentations at gastroenterology conferences, such as the American College of Gastroenterology Annual Scientific Meeting, are common topics in its releases.
Phathom also issues news on capital markets activity, including proposed and priced underwritten public offerings of common stock and pre-funded warrants, as well as corporate updates such as leadership appointments and participation in investor conferences. Together, these news items provide a view into the company’s GI-focused strategy, clinical pipeline, commercial trajectory, and financing plans. For users tracking PHAT, the news page offers a consolidated stream of these developments over time.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced an expansion of its vonoprazan development program to include non-erosive reflux disease (NERD). This condition affects over 65 million U.S. patients with GERD, with two-thirds suffering from NERD. The program will assess dosage flexibility through clinical trials, with a Phase 2 trial expected to start in mid-2021. The company aims to address limitations in current treatments, utilizing feedback from the FDA. Phathom is simultaneously conducting pivotal trials for erosive esophagitis and H. pylori eradication.
Phathom Pharmaceuticals (Nasdaq: PHAT) announces the completion of patient enrollment in its pivotal Phase 3 clinical trial, PHALCON-EE, for vonoprazan, targeting the healing and maintenance of erosive esophagitis (EE) and heartburn relief. The trial exceeded its enrollment goal of 1,000 patients, with topline results expected in the second half of 2021. This trial complements another study, PHALCON-HP, assessing vonoprazan in H. pylori eradication. Vonoprazan has demonstrated promising efficacy and safety as a potassium-competitive acid blocker, recently receiving Fast Track designation from the FDA.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its management team will participate in two virtual investor conferences in December 2020:
- Evercore ISI 3rd Annual HealthCONx Conference
Date: December 1, 2020
Live Presentation Time: 10:55 am ET - Piper Sandler 32nd Annual Virtual Healthcare Conference
Date: December 2, 2020
Pre-recorded presentation available online
Additionally, one-on-one meetings will be held during these events. For access to the presentations, visit Phathom's website.
Phathom Pharmaceuticals (Nasdaq: PHAT) will host a virtual Investor Day on December 14, 2020, from 1 PM to 3:30 PM ET. The event will feature members of Phathom's management team and gastroenterology experts discussing the company's pipeline and commercial strategy. Interested participants can pre-register for the event. A replay and presentation slides will be available post-event on Phathom's website.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced that its management team will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 3:15 p.m. GMT (10:15 a.m. ET). The conference runs from November 17-19, 2020, where the team will also engage in one-on-one meetings. Interested parties can access the live webcast and recorded presentations via the Phathom website. The company specializes in developing treatments for gastrointestinal diseases, focusing on the novel potassium competitive acid blocker, vonoprazan.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported third-quarter 2020 financial results and provided updates on its pivotal Phase 3 clinical trials for vonoprazan. The company expects to complete enrollment in the PHALCON-EE trial by year-end 2020 and in the PHALCON-HP trial by Q1 2021. Top-line results are anticipated in mid-2021. The net loss for Q3 2020 was $34.1 million, down from $68.1 million in Q3 2019. Cash and equivalents stood at $226.4 million as of September 30, 2020. Phathom is enhancing its team with seasoned biopharmaceutical leaders in preparation for vonoprazan’s potential launch.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced participation in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, at 3:30 p.m. ET. The management team will engage in one-on-one meetings throughout the virtual conference, which runs from September 14-18, 2020. Phathom focuses on developing novel treatments for gastrointestinal diseases, including a late-stage development drug, vonoprazan, aimed at treating acid-related disorders. Recorded sessions will be available for 60 days post-event.
Phathom Pharmaceuticals (Nasdaq: PHAT) reported Q2 2020 results, highlighting a net loss of $21.1 million, significantly reduced from $87.8 million in Q2 2019. This improvement was attributed to lower non-cash charges, which dropped from $57.5 million to $0.8 million. Research and development expenses surged to $14.9 million, reflecting increased clinical costs and staffing. Cash reserves stood at $247.3 million. The company resumed patient enrollment in its Phase 3 trials for vonoprazan, with topline data expected in 2021. Todd Branning was appointed CFO, enhancing the leadership team.
Phathom Pharmaceuticals (NASDAQ: PHAT) has appointed Todd Branning as Chief Financial Officer, transitioning from Interim CFO David Socks, who will remain a strategic advisor and Board member. Branning brings over 25 years of experience in finance from companies like Amneal Pharmaceuticals and Teva Pharmaceuticals, enhancing Phathom's leadership amid the potential commercialization of vonoprazan. This oral potassium-competitive acid blocker has received FDA's Fast Track status for treating H. pylori infection, supporting its promising market position.
Phathom Pharmaceuticals (Nasdaq: PHAT) has restarted patient enrollment in its Phase 3 clinical trials, PHALCON-EE and PHALCON-HP, following a temporary pause due to the COVID-19 pandemic. The trials focus on evaluating the efficacy of vonoprazan, a new treatment for gastrointestinal diseases. Phathom expects to provide top-line data in 2021. The FDA has designated vonoprazan as a qualified infectious disease product, enhancing its development prospects. The trials will assess safety and effectiveness for conditions like erosive esophagitis and H. pylori infection.